The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer

Masahide Matsuyama, Rikio YoshimuraDepartment of Urology, Osaka City University Graduate School of Medicine, Osaka, JapanAbstract: Recent epidemiological studies and animal experiments have demonstrated that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the incidence of colorectal carcinoma....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Masahide Matsuyama, Rikio Yoshimura
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/9c4b5974d80b4752aec1f2075f6a4633
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9c4b5974d80b4752aec1f2075f6a4633
record_format	dspace
spelling	oai:doaj.org-article:9c4b5974d80b4752aec1f2075f6a46332021-12-02T06:14:16ZThe target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer1177-54751177-5491https://doaj.org/article/9c4b5974d80b4752aec1f2075f6a46332008-07-01T00:00:00Zhttp://www.dovepress.com/the-target-of-arachidonic-acid-pathway-is-a-new-anticancer-strategy-fo-a1718https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Masahide Matsuyama, Rikio YoshimuraDepartment of Urology, Osaka City University Graduate School of Medicine, Osaka, JapanAbstract: Recent epidemiological studies and animal experiments have demonstrated that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the incidence of colorectal carcinoma. Cyclooxygenase (COX) is the principal target of NSAIDs. COX is the first oxidase in the process of prostaglandin production from arachidonic acid. COX enzyme may be involved in the initiation and/or the promotion of carcinogenesis due to NSAIDs inhibition of COX. Lipoxygenase (LOX) is also an initial enzyme in the pathway for producing leukotrienes from arachidonic acid. Similar to COX, LOX enzyme may also be involved in the initiation and/or promotion of carcinogenesis. Peroxisome proliferator activator-receptor (PPAR)-&gamma; is a ligand-activated transcriptional factor belonging to the steroid receptor superfamily. PPAR-&gamma; plays a role in both adipocyte differentiation and carcinogenesis. PPAR-&gamma; is one target for cell growth modulation of NSAIDs. In this review, we report the expression of COX-2, LOX and PPAR-&gamma; in human prostate cancer tissues as well as the effects of COX-2 and LOX inhibitors and PPAR-&gamma; ligand.Keywords: cyclooxygenase, lipoxygenase, peroxisome proliferator activator-receptor-&gamma;, prostate cancer Masahide MatsuyamaRikio YoshimuraDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 725-732 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Masahide Matsuyama Rikio Yoshimura The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer
description	Masahide Matsuyama, Rikio YoshimuraDepartment of Urology, Osaka City University Graduate School of Medicine, Osaka, JapanAbstract: Recent epidemiological studies and animal experiments have demonstrated that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the incidence of colorectal carcinoma. Cyclooxygenase (COX) is the principal target of NSAIDs. COX is the first oxidase in the process of prostaglandin production from arachidonic acid. COX enzyme may be involved in the initiation and/or the promotion of carcinogenesis due to NSAIDs inhibition of COX. Lipoxygenase (LOX) is also an initial enzyme in the pathway for producing leukotrienes from arachidonic acid. Similar to COX, LOX enzyme may also be involved in the initiation and/or promotion of carcinogenesis. Peroxisome proliferator activator-receptor (PPAR)-&gamma; is a ligand-activated transcriptional factor belonging to the steroid receptor superfamily. PPAR-&gamma; plays a role in both adipocyte differentiation and carcinogenesis. PPAR-&gamma; is one target for cell growth modulation of NSAIDs. In this review, we report the expression of COX-2, LOX and PPAR-&gamma; in human prostate cancer tissues as well as the effects of COX-2 and LOX inhibitors and PPAR-&gamma; ligand.Keywords: cyclooxygenase, lipoxygenase, peroxisome proliferator activator-receptor-&gamma;, prostate cancer
format	article
author	Masahide Matsuyama Rikio Yoshimura
author_facet	Masahide Matsuyama Rikio Yoshimura
author_sort	Masahide Matsuyama
title	The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer
title_short	The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer
title_full	The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer
title_fullStr	The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer
title_full_unstemmed	The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer
title_sort	target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/9c4b5974d80b4752aec1f2075f6a4633
work_keys_str_mv	AT masahidematsuyama thetargetofarachidonicacidpathwayisanewanticancerstrategyforhumanprostatecancer AT rikioyoshimura thetargetofarachidonicacidpathwayisanewanticancerstrategyforhumanprostatecancer AT masahidematsuyama targetofarachidonicacidpathwayisanewanticancerstrategyforhumanprostatecancer AT rikioyoshimura targetofarachidonicacidpathwayisanewanticancerstrategyforhumanprostatecancer
_version_	1718400004664590336

The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer

Ejemplares similares